No treatment-related deaths were recorded. Further high-throughput biomarker analyses are ongoing. Conclusions: Subtyping-based precision treatment significantly prolonged PFS versus nab-paclitaxel in the first-line treatment of advanced TNBC, with manageable toxicities. Our findings highlight the profound ...
The PD-1– and VEGF-targeted bispecific antibody ivonescimab (SMT112) in combination with nab-paclitaxel (Abraxane) or paclitaxel demonstrated efficacy and safety in the first-line treatment of patients with locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), according to...
“KEYTRUDA plus LENVIMA continues to demonstrate durable clinical benefit as a first-line treatment for patients with advanced renal cell carcinoma, as shown by the clinically meaningful improvement in overall survival ...
LEAP-001 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT03884101) evaluating KEYTRUDA plus LENVIMA versus carboplatin plus paclitaxel for the first-line treatment of advanced or recurrent end...
Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel
Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy Cell Death Dis, 10 (4) (2019), p. 285 View in ScopusGoogle Scholar 24 P. Schmid, H.S. Rugo, S. Adams, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally...
Phase Ib results for its lead oncology asset, CUE-101. The candidate, a novel therapeutic biologic, is being evaluated in combination with Merck’s Keytruda as a potential first-line treatment for patients with HPV-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)....
Background: Triple-negative breast cancer (TNBC) may be more sensitive to platinum. This study was to compare platinum-based regimen with nonplatinum regimen in the first-line treatment of advanced TNBC. Patients and methods: Eligible metastatic TNBC (mTNBC) women without prior treatment for advanc...
This study was to compare platinum-based regimen with nonplatinum regimen in the first-line treatment of advanced TNBC. Patients and methods Eligible metastatic TNBC (mTNBC) women without prior treatment for advanced disease were randomized (1 : 1) to receive either docetaxel–cisplatin (TP) or ...
(FDA) has approved Keytruda , Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastr...